Literature DB >> 2065266

Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495.

C R Freeman1, J Krischer, R A Sanford, M E Cohen, P C Burger, L Kun, E C Halperin, I Crocker, M Wharam.   

Abstract

Between May 1986 and February 1988, 57 patients were accrued to the second dose level of a Phase I/II Pediatric Oncology Group (POG) study exploring the use of hyperfractionated radiation therapy (HRT) in children with high-risk brain stem tumors. Local fields were treated with fraction sizes of 117 cGy given twice daily, with a minimum interfraction interval of 6 hours, to a total dose of 7020 cGy in 60 fractions over 6 weeks. Information regarding clinical status during HRT was available for 55 patients (44 [80%] improved, 6 remained stable, and 5 deteriorated). Results of initial and follow-up computed tomography (CT) scan and/or magnetic resonance imaging (MRI) were available for review for 52 patients. One patient had a complete response (CR) to treatment, 3 had a partial response (PR) (more than 50% response), and 40 remained stable, for a total response rate (CR + PR + stable) of 77%. Median time to disease progression was 6 months. Median survival time was 10 months. Survival rate was 39.6% (standard error [SE] = 6.6%) at 1 year and 23% (SE = 5.8%) at 2 years. Complications of treatment included an enhanced skin reaction in six patients and otitis media and/or externa in nine. One patient bled into tumor shortly after completion of HRT, and three had intralesional necrosis. Five patients continued taking steroids for protracted periods in the face of improved clinical and/or radiologic findings. Complications related to the use of steroids included opportunistic infections, impaired glucose tolerance, hypertension, osteoporosis, and significant mood changes. In no patient was there evidence of any late injury attributable to HRT. When compared with results of treatment with HRT at a lower dose level (6600 cGy), there appears to be a trend toward improved survival at 7020 cGy despite a less favorable patient population at the higher dose level. A second dose escalation to 7560 cGy in 60 fractions over 6 weeks has been implemented as planned.

Entities:  

Mesh:

Year:  1991        PMID: 2065266     DOI: 10.1002/1097-0142(19910801)68:3<474::aid-cncr2820680305>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas.

Authors:  E C Halperin
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

Review 2.  Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy.

Authors:  M T Jennings; M L Freeman; M J Murray
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

3.  Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.

Authors:  Rajni Sethi; Jeffrey Allen; Bernadine Donahue; Matthias Karajannis; Sharon Gardner; Jeffrey Wisoff; Saroj Kunnakkat; Jeena Mathew; David Zagzag; Kia Newman; Ashwatha Narayana
Journal:  J Neurooncol       Date:  2010-07-10       Impact factor: 4.130

4.  Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute.

Authors:  D F Deen; A Chiarodo; E A Grimm; J R Fike; M A Israel; L E Kun; V A Levin; L J Marton; R J Packer; A E Pegg
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

5.  The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma.

Authors:  Antony Michalski; Eric Bouffet; Roger E Taylor; Darren Hargrave; David Walker; Susan Picton; Kathryn Robinson; Barry Pizer; Sylwia Bujkiewicz
Journal:  J Neurooncol       Date:  2010-03-19       Impact factor: 4.130

Review 6.  Diffuse intrinsic pontine glioma-current status and future strategies.

Authors:  Soumen Khatua; Kevin R Moore; Tribh S Vats; John R W Kestle
Journal:  Childs Nerv Syst       Date:  2011-04-30       Impact factor: 1.475

7.  Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG.

Authors:  Ute Bartels; Cynthia Hawkins; Gilbert Vézina; Larry Kun; Mark Souweidane; Eric Bouffet
Journal:  J Neurooncol       Date:  2011-09-08       Impact factor: 4.130

8.  Halo ring supporting the Brown-Roberts-Wells stereotactic frame for fractionated radiotherapy.

Authors:  S Carini; G Scielzo; F Grillo Ruggieri; F Bistolfi; M Ravegnani; L Andreussi
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

9.  Multiple fraction-per-day radiotherapy for patients with brain stem tumors.

Authors:  M E Hebert; E C Halperin; W J Oakes; O B Boyko
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

10.  Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.

Authors:  Nongnuch Sirachainan; Samart Pakakasama; Anannit Visudithbhan; Surang Chiamchanya; Lojana Tuntiyatorn; Mantana Dhanachai; Jiraporn Laothamatas; Suradej Hongeng
Journal:  Neuro Oncol       Date:  2008-06-16       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.